Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Common Equity (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Common Equity for 5 consecutive years, with $20.3 million as the latest value for Q3 2020.

  • On a quarterly basis, Common Equity rose 727.9% to $20.3 million in Q3 2020 year-over-year; TTM through Sep 2020 was $20.3 million, a 727.9% increase, with the full-year FY2019 number at -$4.8 million, down 547.96% from a year prior.
  • Common Equity was $20.3 million for Q3 2020 at Forte Biosciences, down from $24.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $88.6 million in Q2 2017 to a low of -$132.9 million in Q1 2017.
  • A 5-year average of $10.1 million and a median of $9.8 million in 2018 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 547.96% in 2019, then skyrocketed 1076.37% in 2020.
  • Forte Biosciences' Common Equity stood at -$124.4 million in 2016, then surged by 157.13% to $71.1 million in 2017, then tumbled by 101.04% to -$736000.0 in 2018, then tumbled by 547.96% to -$4.8 million in 2019, then soared by 526.06% to $20.3 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Common Equity are $20.3 million (Q3 2020), $24.9 million (Q2 2020), and -$6.8 million (Q1 2020).